News | May 18, 2021
Remdesivir production increased to 119 lakh vials per month
Number of approved manufacturing sites of Remdesivir in the country has increased from 22 sites to 60
Number of approved manufacturing sites of Remdesivir in the country has increased from 22 sites to 60
The outlook for the US business remains good as respiratory pipeline (gAbraxane, gAdvair, gDulera) adds medium-term growth visibility.
Dr. Reddy's has the rights to distribute 250mn doses in India
The company plans to aggressively invest in longer gestation period projects like innovation, biosimilars, vaccines, etc.
The company will provide one crore tablets every week, starting from 12th May 2021, aggregating to 16 crore tablets worth Rs. 8 crores over the next 4 months
Proactively engaging with foreign vaccine manufacturers like Moderna, Pfizer etc., to apply for Emergency Use Authorization in India so that these vaccines can be easily imported and made available in India
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)
Subscribe To Our Newsletter & Stay Updated
